Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences

TUSTIN, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December.  Steven W. King, president and chief executive officer, will participate in a panel discussion focused on cancer immunotherapy at Piper Jaffray’s 27th Annual Healthcare Conference.  Additionally, the company will be one of only 16 life science companies attending Roth Capital Partners’ Immuno-Oncology Corporate Access Day.

Details of Peregrine’s Piper Jaffray conference participation are as follows:
Conference:  Piper Jaffray 27th Annual Healthcare Conference
Date:  December 1-2, 2015
Panel Title: Under-Discovered OncoInnovators
Panel Time: December 1, 2015, 3:00 – 4:00 p.m. (Eastern)
Location:  Lotte New York Palace Hotel
Details of Peregrine’s Roth Capital Partners conference participation are as follows:
Conference: Roth Capital Partners Immuno-Oncology Corporate Access Day
Date:  December 16, 2015
Location: Park Hyatt New York Hotel

About Bavituximab: A Targeted Investigational Immunotherapy

Bavituximab is an investigational chimeric monoclonal antibody that targets phosphatidylserine (PS). Signals from PS inhibit the ability of immune cells to recognize and fight tumors. Bavituximab, the lead compound in Peregrine's immuno-oncology development program, blocks PS to remove this immunosuppressive signal and sends an alternate immune activating signal.   PS targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in robust anti-tumor immune responses. 

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.  Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit


Contact Data